CHARLES GREESON: Open Payments
NPI 1003919994 · SAN ANGELO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$984 in 56 payments from 14 companies in 2025. Trend: 2023 $449 · 2024 $531 · 2025 $984
Food & beverage: $984
| Company | Payments | Amount |
|---|---|---|
| Galderma Laboratories, L.P. | 20 | $165 |
| GENZYME CORPORATION | 3 | $158 |
| Janssen Biotech, Inc. | 9 | $148 |
| Regeneron Healthcare Solutions, Inc. | 4 | $135 |
| UCB, Inc. | 5 | $102 |
| Novartis Pharmaceuticals Corporation | 4 | $88 |
| Arcutis Biotherapeutics, Inc. | 4 | $62 |
| Krystal Biotech Inc | 1 | $24 |
| Kerecis Limited | 1 | $22 |
| ABBVIE INC. | 1 | $20 |
Products named: DUPIXENT, NEMLUVIO, TREMFYA, Bimzelx, Zoryve, Rhapsido, COSENTYX, VYJUVEK.
Industry payments across TX — which companies pay providers there.
